Creative Biolabs provides industry-leading aptamer optimization services designed to refine raw SELEX sequences into high-performance molecular tools. We help researchers overcome binding instability and low sensitivity, ensuring your candidate is perfectly tailored for diagnostic, environmental, or industrial applications.
Contact our team to get an inquiry now!Aptamers are single-stranded oligonucleotides, DNA or RNA, capable of folding into intricate three-dimensional architectures to bind targets with high specificity. While the SELEX process identifies functional binders, raw aptamers often suffer from nuclease sensitivity and suboptimal affinity in complex matrices. Aptamer optimization is the critical engineering phase that follows discovery. It involves modifying the chemical backbone and refining the primary sequence to enhance thermal stability and binding kinetics. By integrating structural truncation with advanced chemical engineering, we transform discovery-stage sequences into robust, stable reagents capable of maintaining peak performance in challenging physiological or industrial environments, effectively bridging the gap between a library hit and a functional product.
Fig.1 Optimization strategies of aptamer.1,3
We provide a comprehensive suite of post-SELEX engineering strategies to maximize the utility of your oligonucleotide binders. Our team evaluates your sequence's secondary structure to implement precise modifications that enhance affinity, durability, and target selectivity.
Our Core Service Offerings:
We utilize systematic deletion analysis and secondary structure modeling to identify the essential binding domain. By removing non-functional "flanking" sequences, we reduce synthesis costs and minimize non-specific interactions without compromising target affinity.
Many aptamers lose function when moved from selection buffers to real-world environments. We utilize massively parallel screening (MPS) to identify rare mutations that stabilize the aptamer's fold in the presence of varying salt concentrations and temperatures.
To improve binding to hydrophobic protein pockets, we introduce non-natural base modifications. This "chemical vocabulary" expansion allows our engineered aptamers to achieve specificity levels that traditional four-base oligonucleotides cannot reach.
We fortify your candidates against degradation using 2'-ribose modifications (2'-F, 2'-OMe) and Phosphorothioate (PS) linkages. We also offer Locked Nucleic Acids (LNA) to significantly increase the melting temperature (Tm) of the binding complex.
We provide site-specific conjugation of functional groups, including PEGylation for half-life extension, cholesterol for membrane permeability, or fluorophores and biotin for diagnostic assay integration.
Beyond simple sequence tweaks, we perform bivalent or multivalent construction. By linking multiple aptamer units, we increase the functional avidity, allowing for the detection of targets at picomolar concentrations.
Technical Consultation: You provide the initial aptamer sequence and its known target affinity.
Feasibility Assessment: We analyze the sequence in silico to predict folding and potential truncation sites.
Strategy Design: A custom optimization roadmap is created, selecting specific chemical modifications or truncation patterns.
Synthesis & Modification: Our laboratory synthesizes the modified variants using high-fidelity phosphoramidite chemistry.
Affinity Validation: We verify the Kd and specificity of the optimized variants using liquid-phase assays or surface plasmon resonance (SPR).
Data Delivery: You receive a comprehensive report containing the optimized sequence, binding kinetics data, and the final purified product.
Fig.2 Secondary structures and function of the original OTA aptamer and its variants.2,3
In this study on Ochratoxin A (OTA) detection, researchers used NMR spectroscopy to resolve the structure of the OTA aptamer. By identifying the G-quadruplex and duplex motifs critical for target recognition, they performed precision sequence refinement. The resulting "super-aptamer," featuring a single-base mutation and a truncated sequence, demonstrated a 100-fold increase in binding affinity. This optimization also enhanced thermal stability and structural rigidity, significantly boosting performance in high-sensitivity biosensors. This case proves that structure-guided engineering, not just simple truncation, is essential to unlocking an aptamer's full therapeutic and diagnostic potential.
A: Shortening the sequence eliminates non-essential nucleotides that may fold into "decoy" structures. By focusing on the binding core, we reduce non-specific interactions and lower the cost of large-scale chemical synthesis.
A: Absolutely. We frequently take sequences discovered via standard SELEX and apply our advanced optimization pillars to improve their stability, affinity, and specificity for specific end uses.
A: We employ specificity screening against closely related molecules. Our high-throughput platforms allow us to measure binding across a panel of analogs simultaneously to ensure "lock-and-key" precision.
A: Yes, we utilize LNAs and specific backbone modifications that significantly increase the thermal melting point, allowing the aptamer to function at elevated temperatures.
A: We optimize both DNA and RNA sequences. For RNA, we focus heavily on 2'-position modifications to ensure the resulting candidate is resistant to ubiquitous RNase enzymes.
As a pioneer and the undisputed global leader in novel drug discovery and manufacturing, Creative Biolabs has won a good reputation in providing support for aptamer development and optimization. Our professional scientists are confident in offering domestic and international customers a range of tailored strategies and services for the optimization of aptamers.
All you need to do is contact us directly and communicate with us about your specific demands or ideas. Our seasoned scientists will reply to you with a custom solution as soon as possible.
| Cat# | Product Type | Product Name | Specie Reactivity | Applications | Inquiry |
|---|---|---|---|---|---|
| CTS-006 | Serum | Human Complement Serum (Pooled) | Human | Complement fixation assays; Haemolysis Assays | INQUIRY |
| CTS-001 | Serum | Guinea Pig Complement Serum | Guinea pig | Complement fixation assays; Haemolysis Assays | INQUIRY |
| CTR-001 | Antibody | Hemolysin (Rabbit Anti-Sheep Cell Hemolysin) | Sheep | Complement fixation assays; Haemolysis Assays | INQUIRY |
| CTP-461 | Protein | Native Human Complement C1q Protein | Human | ELISA; Functional Assays | INQUIRY |
| CTP-463 | Protein | Native Mouse Complement C1q Protein | Mouse | ELISA; Functional Assays | INQUIRY |
| CTMM-0322-JL15 | Antibody | Mouse Anti-Human C1q Monoclonal Antibody (TJL-03) [HRP] | Human | WB; IHC; ELISA | INQUIRY |
| CTP-051 | Protein | Native Human Complement C3b Protein | Human | ELISA; Functional Assays | INQUIRY |
| CTP-456 | Protein | Native Cynomolgus Monkey Complement C3b Protein | Cynomolgus Monkey | ELISA; Functional Assays | INQUIRY |
| CTApt-113 | Aptamer | Anti-Thrombin Aptamer | Anticoagulant Studies; Structural Complexes; Coagulation Monitoring | INQUIRY | |
| CTApt-217 | Aptamer | Anti-Interleukin 6 (IL-6) Aptamer | ELISA-Like Detection; Inflammatory Disease Screening | INQUIRY | |
| CTApt-615 | Aptamer | Anti-EGFR Aptamer | Targeted Delivery; Cell Internalization; Molecular Imaging | INQUIRY |
References